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Abstract
Background: Patients with chronic hepatitis C virus (HCV) experience reduced quality of life, HCV-associated symptoms,
comorbid conditions, and treatment side effects. The Cognitive Behavioral Coping Skills group intervention for HCV
(CBCS-HCV) was developed using the Stage Model of Behavioral Therapies Research. Intervention development and initial
feasibility testing in wave 1 participants were previously reported. The primary objective of this subsequent pilot with
wave 2–3 participants was to investigate the effect sizes and clinical improvements in patient-reported outcomes (PROs)
and trial and intervention feasibility.
Methods: A pilot feasibility two-arm randomized controlled trial using block randomization to assign patients to CBCS-
HCV or standard of care was conducted. Participants attended nine group sessions: four before HCV treatment and five
during treatment. PRO data were collected at five time points: before the CBCS intervention (T1), immediately before HCV
treatment (T2), during HCV treatment (T3, T4), and 1 month post-intervention/post-HCV treatment (T5). PROs included
quality of life, perceived stress, HCV symptoms, and medication adherence. Cohen’s d was used to estimate within-group
changes (WGCs) and between-group differences (BGDs), with d > 0.35 considered potentially clinically significant. Potential
mechanisms of change were also evaluated.
Results: Several WGCs and BGDs (ES > .35) suggest that the CBCS-HCV may promote improvements in PROs:
psychological stress, depression, anger, anxiety, sleep disturbance, and fatigue. The intervention did not appear
to impact social functioning, pain, or medication adherence. Cognitive behavioral skills and group therapy dynamics, but
not HCV treatment self-efficacy, may mediate improvements in PROs. Most aspects of the study trial, including intervention
implementation, were feasible. Patient acceptance and retention were exceptional. The greatest feasibility challenge was
due to patients needing to initiate treatment as soon as medications were obtained, but often before a full block could be
created in wave 3. Challenges with PRO data collection were identified that will be resolved in future studies.
Conclusions: The CBCS-HCV intervention warrants future investigation in an efficacy trial to evaluate improvements in
selected PROs. The next step is to pilot test the CBCS-HCV delivered via telehealth to an expanded pool of patients to
reduce patient barriers, hone technical logistics, and improve intervention reach and effectiveness.
Trial registration: NCT03057236 Retrospectively registered.
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Background
Chronic hepatitis C virus (HCV) affects over three million
people in the USA and can lead to advanced liver disease,
liver-related mortality, and all-cause mortality [1, 2]. Pa-
tients complain of several diffuse symptoms that may be
associated with HCV and report poor health-related quality
of life (HRQOL) [3, 4]. Antiviral treatment can eradicate
HCV but can be difficult to tolerate for some patients [5].
Despite the availability of more tolerable and effective treat-
ments, there remains a substantial need to develop psycho-
social interventions to improve the health and well-being of
the underserved HCV population [6]. There is also a need
in clinical hepatology studies to capture patient-reported
experiences using patient-reported outcome measures
(PROMs) to complement traditional clinician-reported
adverse events and laboratory markers [7, 8]. Psychosocial
interventions could enhance patients’ coping skills to miti-
gate the negative impact of disease, and treatment in pa-
tients have difficulty coping with treatment side effects.
Additionally, newer regimens are allowing more individ-
uals to undergo treatment (i.e. traditionally “difficult to
treat” patients with psychiatric or addiction issues); how-
ever, this introduces new clinical challenges for treatment
providers. Psychosocial interventions provided before or
during HCV treatment could provide patients with ancil-
lary support and skills training that medical providers do
not have the time nor expertise to provide [9, 10]. Finally,
the current repertoire of healthcare services available for
HCV patients is woefully limited. Many patients do not
meet the eligibility requirements for insurance approvals
of HCV treatment and are left with no other healthcare al-
ternatives to enhance overall health and well-being [11].
Therefore, psychosocial interventions could be useful for
patients awaiting treatment, undergoing treatment, or
those who have completed treatment but are still living
with advanced liver disease or cirrhosis. Psychosocial in-
terventions that assist patients in developing cognitive and
behavioral coping skills have been around for decades.
PROMs are often the best method for evaluating clinical
improvements in mental and physical health outcomes in
other medical populations but are used less often in clin-
ical hepatology studies [8].
To address the gap in healthcare services for HCV pa-
tients, we developed the Cognitive Behavioral Coping
Skills group intervention for HCV (CBCS-HCV), an
intervention that was modified specifically for the needs
of HCV patients undergoing antiviral therapy. Several
novel PROMs were used to evaluate improvements in
functioning, stress, and symptoms which have not previ-
ously been utilized in hepatology studies. The formative
work, preliminary study protocol, and initial pilot feasi-
bility testing of the CBCS-HCV in an initial wave of par-
ticipants (“wave 1”) undergoing interferon-based therapy
have been previously described [12]. As discussed in the
prior article, we followed the Stage Model for Behavioral
Therapies Research guide to develop the CBCS-HCV
[13]. In the initial phase of this research program, we ad-
dressed several essential steps recommended in stage 1a
and stage 1b research. First, we performed several re-
search activities, such as a literature review, a patients’
needs assessment, and selected pre-existing intervention
materials to modify for the CBCS-HCV [12]. Next, we
developed the CBCS-HCV group intervention Patient
Workbook and Therapist Guide and a preliminary study
protocol to conduct a mini randomized controlled trial
(RCT). Several PROs were selected to evaluate a broad
array of potential outcomes that we speculated might be
affected by the intervention. Finally, we conducted initial
feasibility and pilot testing in wave 1 study participants
to evaluate (a) patient acceptability; (b) feasibility of re-
cruitment, randomization, retention, and PRO data col-
lection; (c) feasibility of intervention delivery; and (d)
therapist protocol fidelity [12].
Several lessons were learned during the initial pilot
testing. Patient acceptability was exceptional, therapist
protocol fidelity was high, and participation, retention,
and data collection were successful [12]. The major chal-
lenge was enrollment impediments that prevented block
randomization due to providers and patients deferring
HCV treatment until newer treatment regimens were
available. These challenges were viewed as temporary
and unlikely to impede future piloting. Because patient
acceptability of the CBCS-HCV was high and the major-
ity of other study and intervention methods were found
feasible, we elected to move forward with additional
pilot testing with wave 2 and wave 3 study participants
to address two additional essential research activities
recommended by the Stage Model of Behavioral Therap-
ies prior to conducting a full efficacy study [12].
We placed emphasis on selecting and evaluating novel
PROs not often utilized in clinical hepatology studies,
although objective markers (viral load, pill count) were
collected as well. Many clinical hepatology studies are
based on clinician-reported adverse events or improve-
ments, which do not correlate well with patient-reported
harms or improvements [14, 15]. Since the focus of this
pilot study was a psychological/behavioral intervention,
it was critical to capture clinical improvements from the
patients’ perspective. Selection of PROs was partially
based on the Wilson and Cleary classification scheme
[16]. The model suggests that to be very precise and
valid, distinctly different PROs should be assessed sep-
arately to maximize information and decrease overlap
between constructs. Symptoms and side effects are the
most proximally and least confounded clinical variables
associated with disease and treatment; however, as one
moves further away from the direct effects of disease
and treatment, towards the broader construct of quality
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of life, many other confounding patient and environmen-
tal factors influence a quality of life score. Therefore, we
selected several PROMs that captured unidimensional
patient-reported symptoms (e.g., fatigue, depression, sleep,
pain) most closely related to HCV and least confounded
by other influences. This would allow us to determine
within the pilot study, the precise outcomes that could be
affected by the intervention.
The primary objectives of this follow-up pilot feasibility
study in wave 2 and 3 study participants were as follows:
(1) to examine effect size (ES) estimates of change in spe-
cific PROs, (2) to determine whether clinically significant
improvements occurred in any specific PROs, and (3) to
continue to evaluate study feasibility elements to inform a
larger efficacy study. This information can be used to in-
form the selection of PROs and sample size calculations
for a future efficacy trial. To achieve our first objective, we
calculated ES estimates for all potential PROs to examine
within-group changes (WGCs) over time and between-
group differences (BGDs) at various time points. To
achieve our second objective, we focused on ES esti-
mates from baseline (T1) to the start of HCV treatment
(T2), which aligned with receipt of four out of the nine
CBCS-HCV sessions to determine the impact of half of
the intervention on PROs prior to HCV treatment initi-
ation. We also focused on ES estimates from baseline
(T1) to 1 month post-CBCS-HCV intervention/post-
HCV treatment (T5) to examine sustained clinical im-
provements post-intervention/post-treatment. We did
not anticipate improvements in PROs during HCV treat-
ment in the treatment condition because treatment side ef-
fects could lead to worse PRO scores, but we speculated
that symptoms might either stabilize, or not worsen, during
treatment. We selected an ES estimate of d > 0.35 as the
threshold to define a potentially clinically significant im-
provement in a PRO, as it represented a small to moderate
effect size and would be worthy of testing in a future effi-
cacy trial. Study feasibility elements evaluated to address
the third objective included feasibility of a RCT study de-
sign, intervention delivery, patient acceptability, therapist
protocol fidelity, recruitment, enrollment, attendance, re-
tention, and PRO data collection.
Methods
Study design
A detailed description of the preliminary study design
and methods for an RCT of the CBCS-HCV interven-
tion with wave 1 participants has been published [12].
Only a brief description of the study protocol conducted
with wave 2 and 3 study participants is provided below.
To test the feasibility of conducting a future RCT, the
pilot feasibility study was designed as a two-arm RCT
with study participants randomized to CBCS-HCV (n = 12)
or standard of care (SC; n = 12). We sought to randomize
patients for wave 2 when a block of 12 patients were con-
sented and to repeat this procedure for wave 3 when a sec-
ond block of 12 patients were consented. In this paper, we
briefly describe the updated version of the study protocol,
feasibility of implementation, and PRO results in wave 2
and wave 3 pilot testing for further refinement to prepare
for a larger efficacy study.
Inclusion/exclusion criteria
We applied the same criteria that were used during wave
1 piloting to the current study, with the exception of
two changes. Only patients prescribed a 12-week HCV
regimen were eligible (i.e., patients prescribed 24-week
regimens were excluded) so that all patients were main-
tained on the same intervention and PRO assessment
schedule during and after the intervention. Secondly, pa-
tients co-infected with HIV or hepatitis B were included
to increase the pool of eligible patients and mirror the
type of patients seen in clinical practice.
Screening and recruitment
Recruitment of 12 patients to enroll in wave 2 occurred
in March 2014. Recruitment of 12 patients to enroll in
wave 3 occurred from the end of April to the beginning
of July in 2014. Data collection was completed in December
2014. Potentially eligible patients were pre-screened from a
treatment waitlist, and those potentially eligible were con-
tacted to determine eligibility and interest. Screening and
recruitment were conducted by two trained research coor-
dinators. Interested patients attended a baseline research
visit after participating in the informed consent process.
Randomization
A biostatistician developed a computer-based randomization
procedure to conduct randomization. The protocol dictated
that when a group of 12 eligible patients were consented for
wave 2, study participants would be randomized to CBCS-
HCV (n= 6) and SC (n= 6) using a block randomization
procedure. The procedure was then repeated to randomize
and enroll 12 patients for wave 3. Enrolled participants were
contacted later by a research coordinator and informed of
group assignment.
Standard of care (SC) condition
Participants randomized to SC were able to proceed with
initiating HCV treatment per standard clinical procedures
and were followed and managed by the liver clinicians. At
the time of recruitment for wave 2–3 in 2014, two first-
generation direct-acting antiviral (DAA) therapies were
being used in standard clinical care: simeprevir/sofosbuvir
and sofosbuvir/ribavirin [17]. All study subjects were pre-
scribed one of these two regimens. The first regimen in-
volved two pills dosed once per day, while the second
regimen contained 7 pills and was dosed half in the
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morning and half at bedtime. Standard clinical procedures
encouraged patients to attend regular follow-up treatment
visits to monitor safety and efficacy at treatment weeks 2,
4, 6, 8, and 12, but all of these visits were not required if
patients were doing well. Data collection of paper and
pencil PROMs was married to these clinic visits. Standard
labs were drawn according to clinical protocol and not for
research purposes.
CBCS-HCV intervention condition
The content of the CBCS-HCV intervention was the
same as that delivered in wave 1 with two exceptions.
Updates were made, as needed, to certain sections (e.g.,
description of new medications). Secondly, feedback re-
ceived after wave 1 piloting favored extending the length
of each weekly session and adding additional sessions to
allow for more group discussion and practice. However,
due to insurance restrictions, the clinical team needed
patients to start HCV treatment within 1–2 weeks of
obtaining their medications or else risk having future re-
fills denied. Due to this restrictive timeline, we needed
to condense the CBCS-HCV modules into nine, 2-h ses-
sions: four weekly sessions prior to starting HCV treat-
ment and five sessions delivered at HCV treatment
weeks 2, 4, 6, 8, and 12. A description of the condensed
modules covered in 9 sessions is provided in Table 1.
The study therapist was the same PhD-level licensed
clinical psychologist who facilitated the group during
wave 1 pilot testing.
PROM data collection schedule
Based on experiences during wave 1 pilot testing, we al-
tered the assessment schedule to capture the PROs for
waves 2 and 3. In the current pilot study, we wanted to cap-
ture PROs more frequently during the CBCS intervention;
therefore, we added an additional PRO assessment after
session #8 of the CBCS (aligned with treatment week 8). It
was also important to capture post-intervention PRO data
closer to the end of the intervention; therefore, we moved
the post-intervention PRO assessment from 3 months to
1 month post-intervention. The PRO assessment schedule
was as follows:
T1: baseline PRO assessment after consent in both
conditions
T2: 1–2 weeks before starting HCV treatment (aligned
with after session #4 in the CBCS condition)
T3: at treatment week 8 (aligned with after session #8
in the CBCS condition)
T4: at the end of HCV treatment at week 12 (aligned
with after final session #9 in the CBCS condition)
T5: at 1-month post-intervention/post-HCV treatment.
Based on negative experiences during wave 1 using
electronic monitoring pill caps to objectively measure
medication adherence, we decided to measure adherence
using only pill counts and patient self-report. Electronic
monitoring caps were eliminated. Medication adherence
(pill counts, self-report) was evaluated at every clinic visit
attended during treatment (weeks 2, 4, 6, 8, and 12).
Participant reimbursement
Participants in each condition were compensated $25
for completion of each of the five PRO assessments T1–
T5. For wave 2, CBCS-HCV participants were compen-
sated $25 for attendance at each of the 9 group sessions.
Table 1 Content of nine CBCS-HCV group modules
Module Relaxation training Review and application of previous skills Training in new topic and skills
1 Progressive muscle relaxation (PMR) • Introductions
• Group expectations
• Intro and overview
• Positive lifestyle changes
2 Diaphragmatic breathing • Positive lifestyle changes • Stress awareness and appraisal
• Lifestyle changes
3 Autogenic training • Stress and appraisal
• Lifestyle changes
• Negative automatic thoughts
• Cognitive distortions
4 Healing wellness imagery • Negative automatic thoughts
• Cognitive distortions
• Cognitive restructuring
5 Light imagery • Cognitive restructuring • Coping with stress and symptoms
6 Passive PMR • Coping with stress and symptoms • Cognitive-behavior skills for depression
• Behavioral activation
• Pleasurable activities
7 Immune system guided imagery • Cognitive-behavioral skills for depression
• Behavioral activation
• Pleasurable activities
• Activity-rest cycles
• Sleep hygiene
8 Self-forgiveness script • Activity-rest cycles
• Sleep hygiene
• Anger prevention/management
• Interpersonal effectiveness
9 Mindfulness • Anger prevention/management
• Interpersonal effectiveness
• Assertive communication
• Interpersonal effectiveness
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To enhance recruitment for wave 3, participants
assigned to the CBCS-HCV intervention were reim-
bursed $100 to attend each of the first four pre-
treatment CBCS sessions to help defray travel cost for
research only, non-clinical visits.
Measures
PROMs
See detailed description of the PROMs in our previous
article [12]. PROMs were collected via paper and pencil,
typically after regular clinical visits and sometimes via
post mail if clinical visits did not align with the PRO
assessment schedule. Generic health-related quality of life
(HRQOL) was measured using the Functional Assessment
of Cancer Therapy-General Population (FACT-GP) instru-
ment [18]. The FACT-GP instrument has a total score and
four subscales: physical well-being, social/family well-being,
emotional well-being, and functional well-being. Perceived
stress was measured using the Perceived Stress Scale (PSS)
[19]. Precise HCV symptoms and treatment side effects
were measured using eight short instruments from the
National Institutes of Health (NIH) Patient-Reported Out-
comes Measurement Information System® (PROMIS®):
depression—8; irritability—8; anxiety—4; fatigue—8; sleep
disturbance—8; sleep-related impairment—8; pain inten-
sity—3; and pain interference—4 [20, 21]. Medication ad-
herence was measured at each treatment clinic visit using
pill counts and self-report, per protocol described previ-
ously [12]. Pill count was conducted for all oral medica-
tions. Medical records were reviewed for laboratory data,
specifically HCV RNA viral load at 4 or 12 weeks post-
HCV treatment to determine if the virus was detectable or
undetectable.
Process measures
See description in previous article [12]. Because it will
be important to measure potential mechanisms by which
clinical gains are made in a future efficacy study, we
piloted three PRO surveys that could potentially capture
putative mechanisms: active CBCS skills (e.g., relaxation,
awareness of tension, assertiveness, coping confidence)
using the Measure of Current Status (MOCS) [22], HCV
treatment self-efficacy [23], and nonspecific therapeutic
aspects of group therapy [24–26].
Study feasibility measures
Similar to the protocol implemented in wave 1 pilot test-
ing, we evaluated the feasibility of the following study ele-
ments: (a) feasibility of randomization based on the ability
to randomize and enroll a block of 12 participants; (b) re-
cruitment and enrollment efforts as evidenced by the pro-
portion of patients screened, consented, and enrolled; (c)
retention efforts based on the number of CBCS-HCV ses-
sions attended and the proportion of patients who started
and completed the CBCS-HCV intervention; and (e) the
feasibility of data collection by the average of data points
completed at each assessment period.
Therapist protocol fidelity measures
Therapist’s adherence and competency with delivery
of CBCS-HCV modules Details of this measure are de-
scribed elsewhere [12]. Study staff observed the delivery
of the CBCS-HCV using a 0–100% rating scale to track
the proportion of each module subsection that was com-
pleted according to the protocol. Staff also rated the
therapist’s competency during each session using a 14-
item scale.
Participant acceptability and comprehension scale
Details of this measure are described elsewhere [12].
CBCS participants completed a 14-item survey rating each
session on acceptability.
Data analysis
Data were analyzed in IBM SPSS software v.23 and SAS
(Cary, NC). Descriptive statistics (means, medians, standard
deviations) were calculated for continuous variables. Total
scores and/or subscale scores of each PROM were calcu-
lated per instrument instructions. Higher scores on the
FACT-GP instrument indicate better quality of life. Higher
scores on the PSS indicate higher perceived stress. A pub-
licly available PROMIS® scoring system was used to sum
total raw scores and translate the raw scores into standard-
ized T-scores, which have been calibrated in the US general
population to have a mean of 50 and a standard deviation
(SD) of 10. Thus, a T-score of 40 is one SD below, and
a T-score of 60 is one SD above, the US general popula-
tion mean. For all of the PROMIS® instruments, a higher
T-score indicates a higher degree of that construct (e.g.,
higher depression, higher pain intensity).
Tests of statistical significance were not conducted
as this was a pilot study. The magnitude of difference
between two PRO means were calculated using Cohen’s d
as an estimate of effect size [27]. Cohen’s d was used to in-
dicate the standardized difference between two PRO means
within the same condition over time (i.e., within-group
change (WGC)) and between two conditions at the same
time point (i.e., between-group differences (BGDs)). To de-
termine the difference between two PRO means, Cohen’s d
is defined as the difference between the two means divided
by the pooled standard deviation ((M2 −M1)/SDpooled). We
applied Cohen’s interpretation of ES estimates as follows:
(a) a large ES or magnitude of difference = .80 or 8/10 of a
standard deviation, (b) a moderate ES or magnitude of dif-
ference = .50 or 1/2 of a standard deviation, and (c) a small
ES or magnitude of difference = .20 or 1/5 of a standard de-
viation. ES estimates were calculated for all key PROs to
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determine the magnitude of WGC (e.g., the change in de-
pression mean scores in the CBCS condition from T1 to
T2) and BGD (e.g., depression mean scores in the CBCS
and SC conditions at T2). We focused on potential clinical
improvements (defined as ES > .35) from T1 to T2 in the
CBCS-HCV condition to interpret the impact of having re-
ceived half of the CBCS intervention sessions, in particular
those delivered prior to initiation of HCV treatment, and
from T1 to T5 to evaluate any lasting improvements post-
intervention/post-HCV treatment.
Results
Baseline patient characteristics
Characteristics of study participants are displayed in
Table 2.
PROMs
Means and ESs for all of the PROMs are presented in
Tables 3 and 4, respectively. For each variable, the mean
and ES for both the CBCS and SC condition across all five
time points are provided. Effect sizes connoting WGC from
T1 to all subsequent time frames are provided in paren-
theses after means in Table 4. The third row in Table 4 for
each variable provides the ES for BGD of the CBCS and SC
at each time point (e.g., ES difference between CBCS and
SC at T2). Figures 1, 2, 3, 4, 5, 6, 7, and 8 provide visual
graphs for eight PROMIS® measures over time for both
conditions.
Change from baseline (T1) to start of HCV treatment (T2)
to explore potential benefits after participation in four
CBCS-HCV sessions
As shown in Tables 3 and 4, the CBCS-HCV condition
showed potentially clinically significant improvements (i.e.,
ES > .35) in a variety of PROs, relative to gains made in the
SC condition.
HRQOL and perceived stress
After four CBCS sessions (T1–T2), CBCS participants
had moderate sized ES improvements in overall HRQOL
on the FACT-GP (.38) and physical well-being (.44),
both of which appeared to represent large ES differences
between the two conditions at T2 (.86, .90). The CBCS
group also demonstrated moderate ES improvements in
perceived stress levels (.53), and this represented a large
ES difference between the two conditions at T2 (.90).
Table 2 Patient characteristics
CBCS (n = 9) SOC (n = 11) Total (n = 20)
N (%) N (%) N (%)
Condition Wave 2 5 (56%) 6 (54%) 11 (55%)
Wave 3 4(44%) 5 (46%) 9 (45%)
Age (years) Mean (range) 63 (56–73) 58 (32–72) 60 (32–73)
Sex Male 5 (56%) 7 (64%) 12 (60%)
Female 4 (44%) 4 (36%) 8 (40%)
Race White 5 (56%) 8 (73%) 13 (65%)
Black 4 (44%) 2 (18%) 6 (30%)
Other 0 (0%) 1 (9%) 1 (5%)
Marital status Single 3 (33%) 43 (36%) 7 (35%)
Married or living with partner 3 (33%) 5 (46%) 8 (40%)
Separated, divorced, or widowed 3 (33%) 2 (18%) 5 (25%)
Education level < 4 year college 4 (44%) 9 (82%) 13 (65%)
≥ 4 year college 5 (56%) 2 (18%) 7 (35%)
Insurance type Private 1 (11%) 6 (55%) 7 (35%)
Medicaid/Medicare 7 (78%) 4 (36%) 11 (55%)
Uninsured 1 (11%) 1 (9%) 2 (10%)
HCV genotype Genotype 1 7 (78%) 6 (55%) 13 (65%)
Genotype 2 or 3 2 (22%) 5 (45%) 7 (35%)
HCV treatment SOF/RBV 2 (22%) 4 (36%) 6 (30%)
SIM/SOF 7 (78%) 7 (64%) 14 (70%)
Cirrhosis Yes 2 (22%) 5 (45%) 7 (35%)
No 7 (78%) 6 (55%) 13 (65%)
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Table 3 Means, effect sizes for within-group changes (WGCs) from T1 within each condition, and effect sizes for between-group
differences (BGDs) at each time point
PROMs Condition T1 mean T2 mean T3 mean T4 mean T5 mean
HrQOL total CBCS 10.54 11.79 10.46 11.54 12.15
SC 10.06 8.78 10.14 11.61 12.63
HrQOL: physical well-being CBCS 2.65 3.07 2.83 2.83 3.25
SC 2.70 2.24 2.70 2.9 3.04
HrQOL: social/family well-being CBCS 2.79 3.03 2.8 2.96 3.09
SC 2.82 2.71 2.68 3.10 3.16
HrQOL: emotional well-being CBCS 2.72 3.00 2.75 3.17 3.13
SC 2.34 2.50 3.00 3.28 3.25
HrQOL: functional well-being CBCS 2.38 2.69 2.33 2.57 2.69
SC 2.20 1.47 1.67 2.33 2.79
Perceived stress CBCS 1.63 1.27 1.60 1.50 1.29
SC 1.79 2.09 1.91 1.54 1.33
Depression CBCS 54.28 51.54 54.13 51.94 48.61
SC 51.57 53.16 53.88 49.82 51.11
Anger CBCS 50.90 46.50 48.27 50.91 46.68
SC 49.47 50.80 53.70 50.24 51.19
Anxiety CBCS 58.34 54.66 53.66 56.16 53.38
SC 54.64 52.45 54.74 51.68 50.44
Fatigue CBCS 56.51 54.51 54.92 52.88 49.58
SC 59.97 62.61 59.05 55.90 52.46
Sleep disturbance CBCS 54.67 51.81 52.26 51.57 51.69
SC 50.92 49.84 54.44 54.74 50.75
Sleep-related impairment CBCS 52.17 48.79 51.19 49.49 45.40
SC 57.46 63.44 56.42 56.39 52.89
Pain intensity CBCS 47.66 40.57 46.07 49.16 47.08
SC 49.29 47.93 45.75 39.99 39.78
Pain interference CBCS 54.58 50.40 52.93 54.41 53.05
SC 59.56 58.26 58.47 53.31 52.83
MOCS total CBCS 2.25 2.51 2.89 2.92
SC 2.33 2.31 2.60 2.64
MOCS: relaxation CBCS 1.78 2.44 2.89 2.69
SC 1.73 1.65 2.15 2.13
MOCS: awareness of tension CBCS 2.44 2.78 3.11 2.88
SC 2.67 2.53 2.77 3.04
MOCS: assertiveness CBCS 2.44 2.44 2.74 3.25
SC 2.67 2.70 2.77 2.60
MOCS: coping confidence CBCS 2.33 2.38 2.82 2.88
SC 2.27 2.34 2.72 2.79
Tx self-efficacy: patient Comm. CBCS 9.22 8.41
SC 8.79 9.36
Tx self-efficacy: coping with physical CBCS 7.36 6.89
SC 5.61 6.20
Tx self-efficacy: coping with Psych. CBCS 6.87 7.18
SC 7.65 6.42
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Table 4 Effect sizes for within-group changes (WGCs) from T1 within each condition and effect sizes for between-group differences
(BGDs) at each time point
PROMs Condition T1 T2 T3 T4 T5
WGC ESa WGC ESa WGC ESa WGC ESa
HrQOL: physical well-being CBCS .44 .18 .18 .59
SC − .47 .00 .20 .37
(BGD ESb) (− .05) (.92) (.15) (− .06) (.23)
HrQOL: emotional well-being CBCS .33 .03 .52 .54
SC .15 .70 1.07 1.00
(BGD ESb) (.41) (.51) (− .29) (− .14) (− .19)
HrQOL total CBCS .39 − .02 .33 .51
SC − .37 .03 .54 .90
(BGD ESb) (.15) (.86) (.12) (− .03) (− .18)
HrQOL: social/family well-being CBCS .30 .03 .25 .34
SC − .10 − .16 .32 .38
(BGD ESb) (− .04) (.30) (.17) (− .20) (− .08)
HrQOL: functional well-being CBCS − .27 .05 − .18 − .28
SC .66 .51 − .12 − .55
(BGD ESb) (.16) (1.16) (.75) (.24) (− .10)
Perceived stress CBCS − .53 − .06 − .23 − .59
SC .30 .12 − .30 − .54
(BGD ESb) (− .19) (− .90) (− .37) (− .06) (− .06)
Anxiety CBCS − .43 − .46 − .26 − .55
SC − .18 .01 − .28 − .37
(BGD ESb) (.34) (.22) (− .10) (.55) (.30)
Depression CBCS − .28 − .02 − .26 − .55
SC .14 .20 − .18 − .05
(BGD ESb) (.27) (− .14) (.02) (.25) (− .26)
Sleep disturbance CBCS − .51 − .48 − .66 − .53
SC − .28 .76 .92 − .03
(BGD ESb) (.77) (.44) (− .46) (− .81) (.13)
Fatigue CBCS − .14 − .12 − .27 − .52
SC .23 − .08 − .34 − .65
(BGD ESb) (− .27) (− .66) (− .36) (− .23) (− .24)
Sleep-related impairment CBCS − .25 − .07 − .18 − .48
SC .55 − .10 − .10 − .44
(BGD ESb) (− .41) (1.36) (− .45) (− .55) (− .66)
Anger CBCS − .48 − .25 .00 − .46
SC .11 .36 .08 .17
(BGD ESb) (.14) (− .37) (− .46) (.09) (− .55)
Pain interference CBCS − .37 − .15 − .02 − .14
SC − .14 − .12 − .67 − .73
(BGD ESb) (− .53) (− .70) (− .54) (.10) (.02)
Pain intensity CBCS − .64 − .15 .14 − .05
SC − .13 − .35 − .85 − .86
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Table 4 Effect sizes for within-group changes (WGCs) from T1 within each condition and effect sizes for between-group differences
(BGDs) at each time point (Continued)
PROMs Condition T1 T2 T3 T4 T5
WGC ESa WGC ESa WGC ESa WGC ESa
(BGD ESb) (− .15) (− .66) (.03) (.82) (.62)
MOCS: relaxation CBCS 1.06 1.53 1.33
SC − .08 .43 .35
(BGD ESb) (.06) (1.08) (.88) (.55)
MOCS total CBCS .49 1.01 1.30
SC − .04 .43 .44
(BGD ESb) (− .13) (.33) (.47) (.48)
MOCS: assertiveness CBCS .00 .33 1.14
SC .03 .10 − .05
(BGD ESb) (− .22) (− .29) (− .03) (.66)
MOCS: coping confidence CBCS .08 .70 .99
SC .07 .43 .52
(BGD ESb) (.07) (.05) (.12) (.13)
MOCS: awareness of tension CBCS .44 .83 .59
SC − .18 .15 .54
(BGD ESb) (− .29) (.33) (.52) (− .27)
Tx self-efficacy: coping with Psych. CBCS .14
SC − .45
(BGD ESb) (− .31) (.31)
Tx self-efficacy: coping with physical CBCS − .19
SC .22
(BGD ESb) (.61) (.29)
Tx self-efficacy: patient Comm. CBCS − .52
SC .29
(BGD ESb) (.22) (− .60)
aWGC ES is the change over time in the same condition, from T1 to T2, T1 to T3, T1 to T4, and T1 to T5
bBGD ES is the difference between the two conditions at each time point: T1, T2, T3, T4, and T5
Fig. 1 PROMIS depression
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Physical and mental symptoms
With regard to changes in baseline symptoms, the CBCS
condition showed moderate ES benefits in several symp-
toms after only four CBCS sessions, including improve-
ments in anger (.48), anxiety (.43), sleep disturbance
(.51) pain intensity (.64), and pain interference (.37). The
ES differences between the two conditions at T2 were in
the small to moderate ES range for anger (.37), anxiety
(.22), and sleep disturbance (.44) and in the moderate to
large range for pain intensity (.66) and pain interference
(.70). Even though improvements in depression, sleep-
related impairment, and fatigue for the CBCS group
were small over time (.25, .23, .28), these improvements
suggested trends for the CBCS group to improve after
only four CBCS sessions, while these symptoms all wors-
ened during this timeframe in the SC group. The BGD
at T2 was very large (1.35) for sleep impairment and
moderate-to-large for fatigue (.66).
Change from baseline (T1) to 1 month post-CBCS/post-
HCV treatment (T5) to explore potential sustainable
benefits of CBCS intervention after HCV treatment
As shown in Tables 3 and 4, the CBCS-HCV condition
showed potentially significant improvements (i.e., ES > .35)
in a variety of outcome measures from baseline (T1) to
1 month post-CBCS/post-treatment (T5).
HRQOL and perceived stress
In the CBCS group, all HRQOL (FACT-GP) scores im-
proved from baseline to post-CBCS/post-HCV treatment,
with moderate ES improvements in overall HRQOL (.51)
and physical well-being (.59). However, HRQOL in the SC
condition also improved from baseline to 1 month post-
treatment. At 1 month post-CBCS/post-treatment, there
were no significant differences in HRQOL between the two
conditions on any HRQOL subscale. The CBCS group also
demonstrated a moderate improvement in perceived stress
Fig. 2 PROMIS anger
Fig. 3 PROMIS anxiety
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levels (.59), but so did the SC condition (.54), and there was
no difference between the two conditions post-CBCS/post-
treatment (.06).
Physical and mental symptoms
With regard to changes in symptoms from T1 baseline
to 1 month post-CBCS/post-treatment, the CBCS con-
dition showed moderate benefits on most PROMIS®
measures, including improvements in depression (.55),
anger (.46), anxiety (.55), fatigue (.52), sleep disturb-
ance (.53), and sleep-related impairment (.48). No sig-
nificant sustainable improvements were found for pain
intensity and pain interference in the CBCS condition.
The SC condition did not show any improvements in
depression, anger, or sleep disturbance but did show
improvements in fatigue and pain intensity 1 month
post-treatment. The BGDs at 1 month post-treatment
were overall in the moderate range (.26–.66), with
CBCS patients reporting lower depression, anger, fa-
tigue, and sleep-related impairment scores, compared
to patients in the SC condition.
Medication adherence and viral cure
According to the objective pill count data averaged across
all available treatment weeks for both conditions, there
was no difference between the groups in medication ad-
herence. The proportion of ideal versus actual doses taken
by CBCS participants was 96% (84–100%) for all medica-
tions (i.e., SIM, SOF, RBV). One patient in the CBCS con-
dition accidentally double-dosed sofosbuvir for 1 week
bringing down the group average. The proportion of ideal
versus actual doses taken by SC participants was 98%
(91–100%). According to the 7-day self-reported recall
data averaged across all treatment weeks, the propor-
tion of doses taken was 99.9% for the CBCS and 99.6%
for SC. With regard to viral cure, 100% of patients in
both conditions achieved undetectable HCV RNA at 4
or 12 weeks post-HCV treatment, suggesting all had
achieved viral cure.
Potential mechanisms
Active cognitive behavioral ingredients
Tables 3 and 4 display the means and ESs over time
from the MOCS survey which measures patient-reported
Fig. 4 PROMIS sleep disturbance
Fig. 5 PROMIS sleep-related impairment
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cognitive behavioral skill acquisition that the intervention
targeted (i.e., relaxation, assertiveness, awareness of ten-
sion, confidence in coping). CBCS participants reported
a gradual increase in utilization of all cognitive behav-
ioral skills over time, with moderate improvements
after four CBCS sessions (.49) and extremely large im-
provements 1 month post-CBCS (1.30). Improvements
in CBCS participants’ use of relaxation skills increased
over time with extremely large improvements (1.56, 1.
33), and the BGDs of these skills at each time point
ranged from moderate to extremely large. The use of
assertiveness skills increased over time in the CBCS
condition, with an extremely large WGC from baseline
to 1 month post-CBCS (1.14) and a moderately large
BGD (.66) compared to SC at this 1-month post-CBCS
time frame. Awareness of tension increased in the
CBCS condition over time, peaking at the end of the
CBCS intervention with a large ES (.83) and maintain-
ing this skill at 1 month post-CBCS. Confidence in abil-
ity to cope increased over time in both groups with
large ES changes over time for the CBCS condition
(.99) and moderate ES changes in the SC condition.
Self-efficacy
Table 3 displays the means from The Hep C Treatment
Self-Efficacy Survey at T1 and T3 post-CBCS interven-
tion and ESs for three subscales (i.e., confidence in pa-
tient communication, coping with physical symptoms,
coping with psychological symptoms). Higher scores in-
dicate higher patient-reported self-efficacy. In both con-
ditions, all treatment self-efficacy scores stayed the same
or decreased from T1 to T3.
Group therapeutic processes
Nonspecific therapeutic factors of group interventions
(e.g., empathy, group cohesiveness) may positively im-
pact key outcomes. On average, participants reported
that the patient-therapist bond was very positive (M =
6.26, SD = .70) and participants experienced a great deal
of group cohesiveness (M = 6.33, SD = .71). Participants
also reported that their group experience was extremely
favorable (M = 6.29, SD = .71).
Study feasibility measures
The study flowchart is displayed in Fig. 9.
Fig. 6 PROMIS fatigue
Fig. 7 PROMIS pain intensity
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Feasibility of recruitment, enrollment, and randomization
As shown in Fig. 9, the medical records of 64 patients
were reviewed as initial screening process for both waves
2 and 3. Potentially eligible patients were contacted via
telephone. Of 64 screened patients, 27 (42%) consented
to participate in the study, and 22 of the 27 who were
consented (81%) were randomized. The primary reasons
for screen failures were patient barriers to attending in-
person CBCS sessions: proximity to the center, transpor-
tation issues, and work conflicts. Recruitment for wave 2
took approximately 30 days, and recruitment for wave 3
took approximately 64 days. Due to prescription refill re-
quirements, the clinical staff required patients to initiate
HCV treatment within 1–2 weeks of home delivery or
else risk having future refills expire. Thus, we were chal-
lenged with retaining consented patients who had obtained
their medications and were in the queue for randomization,
while concurrently trying to rapidly recruit new patients.
We were able to successfully complete block randomization
of 12 patients as the protocol dictated during wave 2
Fig. 8 PROMIS pain interference
Fig. 9 Study flowchart. Note: two participants withdrew after randomization and baseline due to transportation issues and delays in treatment.
Period of time in which both the CBCS-HCV and SC groups received HCV treatment. Period of time in which only
the CBCS-HCV received the CBCS intervention. Intervention group. Standard of care group. Measurement
time points
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despite these clinical constraints. However, we decided to
conduct block randomization for wave 3 when we had 10,
not 12, consented patients. Five out of 27 patients who
were consented started their HCV treatment before
block randomization could be conducted, leaving 22
to randomize.
Feasibility of study retention
Of the 22 patients randomized, two patients randomized
to CBCS-HCV and who completed baseline T1 data
were withdrawn before the CBCS-HCV intervention
began (see Fig. 1). Therefore, 20 patients (91%) were
retained and completed the full study.
Feasibility of delivery and retention in CBCS-HCV group
intervention
All nine (100%) patients who started the CBCS-HCV
intervention were retained in the study, and none were
lost to follow-up. Attendance at all nine CBCS-HCV ses-
sions was exceptional; only one patient missed the first
session; otherwise, attendance was 100% at every session.
High attendance at these sessions is a strong indicator of
patient enthusiasm and satisfaction with the CBCS-HCV
intervention. There were no patient-reported harms or
unintended effects of the study in either group.
Feasibility of PROM data collection and missing data
The overall rate of data completion for key PROMs via
paper and pencil administration was 89% throughout the
study. Data collection at T1 was 100%. At T2, 75% of
PROMs were collected. Data missed at T2 were all from
the SC group who did not have regular clinic visits
scheduled and who did not return surveys sent via post
mail. Also at T2, four participants (two CBCS, two SC)
completed survey packets after starting HCV treatment
(1–18 days into treatment). A comparison of PRO data
collected during versus before treatment revealed no
trends for outlying data (i.e., the data were in a similar
range for both groups). At T3, 97% of PRO data were
collected. At T4, 95% of PRO data were collected. At
T5, 80% of PRO data were collected with missing data
due to nonattendance at 1-month clinic visits and not
returning surveys via post mail. Finally, we observed in-
complete, poor quality data on four out of 18 observer-
rated therapist protocol fidelity forms (nine sessions ×
two waves), which we were unable to include in the ana-
lysis of protocol fidelity.
Protocol fidelity
According to the protocol, an exclusion criterion was
being prescribed 24 weeks of treatment. However, two
patients in the SC condition were found to be infected
with HCV genotype 3 which required extension of treat-
ment from 12 to 24 weeks. Both participants remained
in the study, and the evaluation of T5 PRO data from
their treatment week 16 visit revealed no concern for
outlying data (i.e., within the range of other scores).
Overall therapist fidelity was 85% in wave 2 and 92% in
wave 3 on the observer-rated protocol fidelity forms
completed after each session. The average observer rat-
ing of the therapist’s competency to conduct each of the
nine modules was 3.9 on a scale ranging from 0 to 4.
The therapist’s competencies that were consistently
rated a four out of four across all nine modules included
warmth, genuineness, showing interest, and empathy.
Patient acceptability
Based on patient report at the end of each of the nine
modules, the average rating across all nine sessions and
all patients was 4.51 on a 5-point scale (SD = 0.18), indi-
cating a high level of satisfaction with the content and
group dynamics. Participants consistently reported that
they had a good session (M = 4.63, SD = .20), group mem-
bers seemed to genuinely care about each other (M = 4.46,
SD = .31), and they intended to remain in the program
(M = 4.87, SD = .11). However, participants also indicated
there was not enough time for discussion and review
(M = 3.76, SD = .57) and there was too much informa-
tion to cover (M = 3.92, SD = .62) during the sessions.
Examples of participants’ written feedback included “I
always enjoy every session,” “I loved all the sessions and
feel they were most beneficial to my day to day living;
wonderful group and facilitators”, “It was good to have
people I could relate to in my group; I have learned to
relax and discuss my problems,” “Affirmation self-talk; I
will definitely practice this,” “Learning about anger; I
learned ways to help control anger using a control plan,”
“Relaxation, learning about imagery, group discussion,”
“I can really use what I learned today to access and posi-
tively modify my thoughts,” “Beginning to recognize
what stresses me,” and “I liked learning how to relax and
what things were stressors and how I act to those
stressors.”
Discussion
The CBCS-HCV pilot and feasibility study findings pre-
sented here extend our previous work with the initial
wave 1 of study participants [12]. Similar to the results
of wave 1, many aspects of the study design, intervention
implementation, and collection of PROMs were feasible.
The group intervention and modules were highly accept-
able to patients. We also identified some specific chal-
lenges to address in future CBCS-HCV studies to improve
study design, implementation, and PROM data collection,
in order to conduct a successful efficacy trial. Importantly,
the findings from this pilot study will aid in the selection
of key PROs to evaluate in subsequent studies.
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The CBCS-HCV intervention appeared to positively
impact several, though not all, of the PROs, with many
effect size estimates suggestive of clinical benefits. Spe-
cifically, patients’ perceptions of stress and some compo-
nents of HRQOL appeared to be positively affected by
the intervention. Moreover, mental health symptoms of
depression, anger, and anxiety showed dramatic im-
provements that were sustained 1 month after HCV
treatment and the intervention were completed, com-
pared to the SC condition. There were also sustained
improvements following the CBCS-HCV intervention
in sleep disturbance and sleep-related impairment, but
not for pain intensity and interference. These prelimin-
ary data suggest which PROs may or may not be im-
pacted by the CBCS-HCV and thus which PROs are
worth investigating in future studies of the CBCS-HCV.
Per Wilson and Cleary, HRQOL is a broad, multi-faceted
construct affected by many confounding variables [16]. We
used the FACT-GP PROM to evaluate HRQOL and found
that the total score and the FACT-GP physical well-being
score improved initially after the first four CBCS modules,
which may have been due to intervention components en-
hancing lifestyle behaviors, such as nutrition, hydration,
physical activity, and sleep hygiene. These improvements in
overall HRQOL and physical well-being were sustained at
1 month post-treatment/post-intervention. In contrast, the
intervention was not intended to directly target family/
social functioning, and thus, it is not surprising that
this subscale score did not change over time. Emotional
and functional well-being were addressed by the inter-
vention, but the FACT-GP subscale score did not im-
prove substantially over time or no differences between
the two conditions were observed on these subscales.
This is inconsistent with the significant improvements
we observed on the PROMIS® depression, anxiety, and
anger PROMs. It may be that the FACT-GP PROM is
too non-specific or multidimensional to capture precise
changes over time and perhaps the PROMIS® short
forms are more sensitive to change.
The Perceived Stress Scale scores improved dramatically
during the CBCS-HCV intervention while stress levels
worsened in the SC condition. CBCS-HCV benefits were
sustained 1 month later; however, perceived stress levels in
the SC group also improved after treatment ended. Stress
reduction in the SC condition could have been due to com-
pletion of antiviral therapy, being cured from HCV, or both.
The CBCS-HCV provides substantial training in stress
reduction techniques, including starting each session with a
new relaxation exercise, and this may account for the
clinical benefits seen early in the CBCS-HCV group.
With many HCV patients having co-occurring mental
health, psychosocial instability, and addiction issues, re-
ductions in psychological stress may be an important
health outcome to target in this population. The Perceived
Stress Scale appears to be an appropriate measure to cap-
ture patient-reported stress improvements and could po-
tentially be complemented in future studies by objective
measures of physiological stress (e.g., cortisol, immune
functioning) [28–30].
The prevalence of mood disorders in the HCV popula-
tion (11–68%) is much higher compared to the general
population (5–12%), particularly for major depression
(24–68%) [31–33]. Our findings suggest that mood dis-
turbance may improve meaningfully as a result of the
CBCS-HCV intervention. Patient-reported depression,
anger, and anxiety improved after four CBCS-HCV ses-
sions, whereas these psychological PROs did not change
in the standard of care condition. Improvements were
maintained 1 month post-intervention in the CBCS group,
whereas depression and anger worsened or stayed the
same in the SC condition. Modules that specifically target
stress reduction, relaxation, and negative thinking may be
responsible for improvements in these PROs and repre-
sent important targets for future studies. The NIH PRO-
MIS® measures may be particularly incisive at capturing
mental and physical symptoms.
Sleep disturbance is a common complaint among pa-
tients with HCV and can affect mental and physical health
[34]. One module was devoted to sleep hygiene tech-
niques, although sleep was discussed in several subsequent
sessions. We found that sleep disturbance improved in the
CBCS-HCV condition relative to the SC condition after
four CBCS sessions and these benefits were maintained
1 month post-intervention. No improvements were ob-
served in the SC group. Sleep-related impairment also im-
proved over time in the CBCS group, with improvements
maintained 1 month post-intervention. Fatigue is one of
the most common features associated with HCV and,
therefore, was addressed via multiple cognitive and behav-
ioral strategies (e.g., relaxation, sleep hygiene, activity-rest
cycles, pacing) [35]. The CBCS group showed improve-
ments in fatigue at 1 month post-intervention; however,
the SC condition also reported less fatigue post-treatment
compared to baseline so that no BGD was observed. It is
difficult to discern the beneficial effects of the intervention
versus viral cure on the 1-month outcomes like fatigue;
however, given that fatigue is such a salient symptom
associated with HCV, it will remain important to address
fatigue symptom improvements in a future efficacy study
and evaluate this important PRO. More time may need to
be devoted to practicing healthy sleep hygiene skills to
augment these modest improvements.
The CBCS-HCV intervention did not produce any last-
ing effects on pain outcomes as measured by the PROMIS®
Pain Intensity and Pain Interference surveys. While initial
reductions were reported, these improvements were not
maintained at 1 month post-intervention, and the SC con-
dition reported less pain at follow-up. Some CBCS-HCV
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intervention modules could have indirectly improved cop-
ing with pain (e.g., relaxation exercises, activity-rest cycling,
cognitive strategies for negative thoughts), but the “dose”
may have been insufficient to create lasting changes.
Moving forward with the CBCS-HCV program, it is un-
likely that pain will be impacted substantially without
adding more pain management training.
Previous studies suggest that HCV patients have worse
mental and physical health compared to the US general
population [4, 36]. Consistent with this literature, our
sample reported worse baseline scores on a majority of
PROMIS® measures relative to the general US population
(T-score = 50) on which the scores were standardized.
However, by 1 month post-intervention, several PROMIS®
scores improved or fell below the population T-score.
Thus, psychosocial interventions like the CBCS-HCV may
aid in normalizing HCV health outcomes to be commen-
surate with the health of the larger US population.
This pilot study sheds light on potential mechanisms,
or mediators of change, that may be partially responsible
for clinical benefits observed in outcomes. PROMs were
the only viable means of capturing subjective patient ex-
periences of mediators that may underlie improvements.
Several specific cognitive behavioral strategies (e.g., re-
laxation) increased over time and may be correlated with
and underlie clinical improvements [37]. Secondly, non-
specific therapeutic processes that were rated as high (e.g.,
group cohesion, acceptance) may also be responsible for
improvements and warrants future examination [38]. In
contrast, the pilot data do not suggest that HCV treatment
self-efficacy improved over time and thus is unlikely to be
responsible for clinical improvements. The CBCS-HCV
intervention was not specifically designed to target the four
foundations of self-efficacy [39], which might explain the
lack of change seen on this scale. In a future efficacy study,
a secondary analysis of changes in mechanisms (i.e., medi-
ating variables) correlated with changes in outcome vari-
ables would provide insight into the specific cognitive
behavioral, lifestyle, and group processes that facilitate clin-
ical improvements.
With regard to study feasibility, we identified some
challenges, all of which can be addressed in future
CBCS-HCV studies. The greatest challenge was recruit-
ing patients in rapid succession in order to conduct
block randomization. Another challenge was transporta-
tion issues including long travel distances that precluded
some patients from attending in-person intervention ses-
sions and thus they declined to participate. Thirdly, while
PRO data collection was satisfactory (89%), we identified
issues to address in future studies to enhance PRO com-
pletion rates. These issues can be mitigated by improving
coordinator training, real-time quality assurance checks,
and using phone-based or electronic data capture systems,
such as REDCap (https://www.project-redcap.org/). Paper
and pencil administration of PROMs can be fraught with
human error if not monitored in real-time. Thus, future
studies will transition to PRO collection via phone-based
surveys or REDCap, which have proven successful in
other studies [40]. Finally, participants recommended
expanding the number of sessions to allow for more
practice, discussion time, and group bonding. A strength
of the study was near-perfect retention in the CBCS-HCV
groups. Strategies that may have increased retention in-
cluded positive group dynamics and peer support and
phone reminder calls from the research coordinators re-
garding date, time, and location of the next group. These
experiences and lessons learned from pilot testing were
tremendously useful and will strengthen future CBCS-
HCV trials and intervention implementation.
Given what we have learned from conducting these
pilot studies, changes to some of the study design fea-
tures and the way in which the CBCS-HCV group inter-
vention is delivered will be needed. For example, it may
be useful to consider offering the CBCS-HCV interven-
tion as an alternative healthcare service to all people
who have been infected with chronic HCV, not just
those embarking on HCV treatment. With prevalence of
mental health and substance use issues, stress manage-
ment modules could address underlying antecedents to
maladaptive cognitions and behaviors. Likewise, lifestyle
modifications (e.g., changes to eating and activity behav-
iors) may improve overall liver health for patients at risk
for other liver diseases, such as those with fatty liver dis-
ease. From a study design perspective, expanding eligi-
bility criteria to all patients with HCV would mitigate
the challenges encountered when recruiting only a sub-
group initiating HCV therapy.
A second consideration involves delivering the CBCS-
HCV group intervention using telehealth videoconferenc-
ing technology, as opposed to in-person groups. Travel
distance and transportation issues are prevalent patient-
level barriers that stymie access to innovative healthcare
services and research studies, particularly in rural states
where patients live long distances from academic medical
centers. Delivery of interventions via telehealth videocon-
ferencing technology may be a cutting-edge alternative to
in-person delivery, supported by a growing body of evi-
dence. Videoconferencing is an efficacious mode of deliv-
ering treatment for a wide range of mental and physical
conditions, and a variety of different interventions have
been delivered including cognitive behavioral, supportive,
and educational [41–45]. Reducing geographical and fi-
nancial barriers may lead to higher rates of study en-
rollment, intervention reach, and clinical effectiveness.
Thus, telehealth platforms like videoconferencing may
increase the reach, uptake, and dissemination of useful
interventions to enhance the overall health of the HCV
population [46].
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Conclusions
In conclusion, we have completed two pilot feasibility
studies with three waves of participants and examined
various elements of feasibility, patient acceptability, and
effect size estimates of clinical improvements in PROs
that may be achieved with the CBCS-HCV [12]. Patient
enthusiasm for the intervention combined with findings
that are suggestive of clinical benefits in psychological
stress, depression, anxiety, anger, fatigue, and sleep all
provide evidence to support further evaluation of the
CBCS-HCV. Several PROMs, namely the PROMIS® short
forms, the Perceived Stress Scale, and the MOCS, appear
sensitive enough to capture diverse and precise improve-
ments in patient outcomes. We conclude that expanding
the eligibility criteria to include all people who have been
infected with HCV and delivering the CBCS-HCV via
videoconferencing telehealth technology would not only
improve future trials, but more importantly, could expand
the dissemination and implementation of this potentially
useful psychosocial intervention for the HCV patient
population.
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